20 Erectile Dysfunction Clinical Trials in Santa Monica, CA (2026)

Q: How do I join a clinical trial in Santa Monica?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Santa Monica research site will contact you.

Recruiting Erectile Dysfunction Studies in Santa Monica

NCT03486873Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...

Santa Monica, CAPHASE33,500 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04638647Recruiting

Secukinumab Open Label Roll-over Extension Protocol

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment w...

Santa Monica, CAPHASE41,000 participantsNovartis Pharmaceuticals

View Study Details

NCT07221357Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untre...

Santa Monica, CAPHASE2990 participantsBristol-Myers Squibb

View Study Details

NCT06112314Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...

Santa Monica, CAPHASE3680 participantsImmunocore Ltd

View Study Details

NCT05123482Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents...

Santa Monica, CAPHASE1460 participantsAstraZeneca

View Study Details

NCT03138161Recruiting

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN given intravenously with defined doses of IPILIMUMAB and NIVOLUMAB based on preliminary results of the Checkma...

Santa Monica, CAPHASE1250 participantsSarcoma Oncology Research Center, LLC

View Study Details

NCT06638307Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer....

Santa Monica, CAPHASE1240 participantsStemline Therapeutics, Inc.

View Study Details

NCT07205718Recruiting

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 m...

Santa Monica, CAPHASE1223 participantsTakeda

View Study Details

NCT06859762Recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors...

Santa Monica, CAPHASE1220 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06795412Recruiting

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

Santa Monica, CAPHASE1220 participantsPyxis Oncology, Inc

View Study Details

NCT04421820Recruiting

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and...

Santa Monica, CAPHASE1220 participantsBold Therapeutics, Inc.

View Study Details

NCT06251310Recruiting

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with...

Santa Monica, CAPHASE1186 participantsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

View Study Details

NCT06679881Recruiting

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angio...

Santa Monica, CAPHASE3170 participantsPharvaris Netherlands B.V.

View Study Details

NCT05270213Recruiting

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endo...

Santa Monica, CAPHASE1164 participantsRiboscience, LLC.

View Study Details

NCT07439653Recruiting

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL...

Santa Monica, CAPHASE1155 participantsTORL Biotherapeutics, LLC

View Study Details

NCT04142437Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with ...

Santa Monica, CA150 participantsBayer

View Study Details

NCT06921928Recruiting

Study for AZD4360 in Participants With Advanced Solid Tumours

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic s...

Santa Monica, CAPHASE1117 participantsAstraZeneca

View Study Details

NCT06234098Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...

Santa Monica, CAPHASE185 participantsAlyssum Therapeutics

View Study Details

NCT07489651Recruiting

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo...

Santa Monica, CAPHASE264 participantsReunion Neuroscience Inc

View Study Details

NCT04890613Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid t...

Santa Monica, CAPHASE152 participantsSenhwa Biosciences, Inc.

View Study Details

About Erectile Dysfunction Clinical Trials in Santa Monica

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 20 erectile dysfunction clinical trials recruiting participants in Santa Monica, CA. These studies are seeking a combined 9,146 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Bristol-Myers Squibb and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in Santa Monica — FAQ

Are there erectile dysfunction clinical trials in Santa Monica?

Yes, there are 20 erectile dysfunction clinical trials currently recruiting in Santa Monica, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Santa Monica?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Santa Monica research site will contact you about next steps.

Are clinical trials in Santa Monica free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Santa Monica studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 20 active trials in Santa Monica are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated July 18, 2026 from ClinicalTrials.gov